跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PAZEO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
PAZEO
Authorized
STANDARD
PAZEO
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
c24f577aea36a4b6
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
c24f577aea36a4b6
Drug Approval Canada Name
PAZEO
Product Name
PAZEO
Status
Marketed
Status Date
2018-03-12
Original Market Date
2018-03-12
Din
02458551
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Ophthalmic
Schedule
Prescription
Ahfs
52:02.00
Atc Original
S01GX09 OLOPATADINE
Atc Name
s 01 gx 09
Aig Number
0132394004
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
OLOPATADINE (OLOPATADINE HYDROCHLORIDE)
0.7 % / W/V
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
c24f577aea36a4b6
Type
Standard
Back to Health Canada Approvals